Thyroid hormones [predominantly 3,5,3-triiodo-L-thyronine (T3)] regulate cholesterol and lipoprotein metabolism, but cardiac effects restrict their use as hypolipidemic drugs. T 3 binds to thyroid hormone receptors (TRs) ␣ and ␤. TR␤ is the predominant isoform in liver, whereas T 3 effects on heart rate are mediated mostly by TR␣. Drugs that target TR␤ or exhibit tissue-selective uptake may improve plasma lipid levels while sparing the heart. Here, we asked how the TR␤-and liver uptake-selective agonist GC-1 influences cholesterol and triglyceride metabolism in euthyroid mice. GC-1 treatment reduced serum cholesterol levels by 25% and serum triglycerides by 75% in chow-fed mice and also attenuated dietinduced hypercholesterolemia. GC-1 reduced plasma high-density lipoprotein cholesterol levels; increased expression of the hepatic high-density lipoprotein receptor, SR-BI; stimulated activity of cholesterol 7␣-hydroxylase; and increased fecal excretion of bile acids. Collectively, these results suggest that GC-1 stimulates important steps in reverse cholesterol transport. Use of TR␤ and uptake selective agonists such as GC-1 should be further explored as a strategy to improve lipid metabolism in dyslipoproteinemia.
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bile acid ͉ lipoprotein ͉ triglycerides ͉ thyroid hormone ͉ selective modulation S trategies that decrease plasma cholesterol levels should prevent and reduce cardiovascular disease (1) . Several lipid-lowering drugs are now available (2) (3) (4) . Most, such as the hydroxymethyl glutaryl CoA (HMG CoA) reductase inhibitors (statins), or bileacid-binding agents, reduce cholesterol levels within liver. This activates sterol regulatory element-binding proteins (SREBPs) (4), thereby inducing low-density lipoprotein (LDL) receptor (LDLR) expression and promoting clearance of LDL cholesterol. Nevertheless, there is a demand for novel therapies to optimize plasma lipids: treatments that promote reverse cholesterol transport (RCT), efflux of cholesterol from peripheral tissues, and excretion of cholesterol should be of particular value (2) (3) (4) .
Several hormones, such as insulin, growth hormone, and thyroid hormone (TH), influence lipid metabolism in part by SREBP-independent pathways (5-7). Thus, modulation of these pathways could offer novel therapies. TH reduces circulating cholesterol (8) . Plasma cholesterol levels are often elevated in hypothyroidism due to reduced LDL turnover, which may be associated with normal or increased triglycerides (9) . Conversely, hyperthyroid patients have reduced plasma cholesterol, also associated with elevated or normal plasma triglycerides (10) . TH action is mediated by nuclear receptors (11, 12) . Separate genes encode TH receptor (TR) subtypes ␣ and ␤, which differ slightly in structure and substantially in tissue distribution. TR␣ regulates heart rate and the speed and force of systolic contraction (13) . TR␤ exerts several metabolic effects (14) , facilitated by high expression in liver (15, 16) .
Because of strong cardiac effects of TR␣ activation (17) , use of TH as hypolipidemic drugs carries significant risks (18) . However, TH derivatives that bind TR␤ selectively or exhibit liver-selective uptake could improve plasma lipids without affecting heart rate (19) . Thus, the TR␤ and liver uptake-selective agonist GC-1 and the TR␤-selective agonist KB141 reduce plasma lipids in animal models, without obvious adverse effects (19) (20) (21) .
The present studies elucidate how GC-1 regulates cholesterol and triglycerides in normal mice. GC-1 reduced serum cholesterol and triglyceride levels, induced up-regulation of the hepatic high-density lipoprotein (HDL) receptor SR-BI, and increased bile acid synthesis and excretion. This suggests that GC-1 stimulates several steps in RCT, and that GC-1 might be a candidate for treatment and prevention of cardiovascular disease in humans.
Materials and Methods
Animals and Experimental Set-Up. Studies were approved by the institutional Animal Care and Use Committee. One hundred eighteen male C57BL͞6 mice, 3 months old (M&B, Ry, Denmark), were kept in standardized conditions with free access to water and normal chow (Lactamin, Kimstad, Sweden). 3,5,3Ј-triiodo-Lthyronine (T 3 ) (Sigma) or GC-1 (22) was administered i.p. in 20% DMSO or propylene glycol for 8 days, once daily at 9:00 a.m.; controls received vehicle. In one experiment, nine groups of six mice were treated with vehicle, or 5.4, 24, 48, and 97 nmol͞kg per day of T 3 or GC-1. The lowest dose of T 3 induces euthyroidism in hypothyroid mice (23) . In another experiment, one group of seven mice was given no additional supplementation; three groups of seven mice received 10% corn oil and 2% cholesterol (cholesterol diet); and three groups of seven mice received 10% corn oil, 2% cholesterol, and 0.5% cholic acid (cholic acid diet). For this experiment, mice were treated with vehicle or 97 nmol͞kg per day GC-1 or T 3 . Food was withdrawn 5 h before kill. Blood was drawn by cardiac puncture under light isoflurane anesthesia. Animals were killed by cervical dislocation. Livers were immediately frozen in liquid nitrogen.
For analysis of bile acid excretion, three groups of five chow-fed mice were treated with vehicle, 48 nmol͞kg per day of GC-1, or T 3 for 5 days. Feces were collected group-wise 24 h before treatment and in the last 24 h of the experiment.
Lipid Analysis. Total cholesterol and triglycerides were determined in individual serum samples by a Monarch automated analyzer (ILS Abbreviations: HMG CoA, hydroxymethyl glutaryl CoA; SREBP, sterol regulatory elementbinding protein; LDL, low-density lipoprotein; LDLR, low-density lipoprotein receptor; VLDL, very low-density lipoprotein; RCT, reverse cholesterol transport; TH, thyroid hormone; TR, TH receptor; HDL, high-density lipoprotein; T3, 3,5,3Ј-triiodo-L-thyronine; SEC, size exclusion chromatography; C4, 7␣-hydroxy-4-cholesten-3-one; CYP7A1, cholesterol 7␣-hydroxylase; SHP, short heterodimerizing partner; LXR, liver X receptor.
Laboratories Scandinavia, Sollentuna, Sweden). Serum triglyceride levels were corrected for free glycerol content. Size exclusion chromatography (SEC) of lipoproteins was performed as described in ref. 24 . Hepatic lipids were extracted (25) and analyzed for cholesterol and triglycerides by using commercial kits (Roche Applied Science, Indianapolis).
Preparation of Hepatic Membranes, Immunoblotting of SR-B1, and
Ligand Blot. Liver membranes were prepared as in ref. 26 and separated on 3-8% Tris-acetate gels (NuPAGE, Invitrogen). Proteins were transferred to 0.45-m nitrocellulose filters. SR-B1 protein was detected with rabbit polyclonal antibodies (1:3,000) against mouse SR-B1 (Novus Biologicals, Littleton, CO) (27) . LDL-receptor expression was determined by ligand blot in nonreduced liver membranes (28).
7␣-Hydroxy-4-Cholesten-3-One (C4). C4 was analyzed in pooled serum samples by HPLC after solid-phase extraction by using 7␤-hydroxy-4-cholesten-3-one as internal standard (29) .
Fecal Bile Acids and Neutral Steroids. Feces were collected groupwise for 24 h. One gram of pooled dried feces was analyzed for neutral sterols (coprostanol, coprostanone, and cholesterol) and bile acids by quantitative gas-liquid chromatography (30) (31) (32) .
Relative Quantitative Real-Time PCR. Total RNA was extracted by TRIzol according to instructions (Life Technologies, Gaithersburg, MD). Total RNA was treated with RNase-free DNAse (Promega). First-strand cDNA synthesis was performed in triplicate for each RNA pool by using random hexamer primers and Omniscript (Qiagen, Valencia, CA). Specific primers (Tables 1  and 2 , which are published as supporting information on the PNAS web site) were designed with primer express and span exon boundaries. Quantification of mRNA used Applied Biosystems PRISM 7700 Sequence Detection System instrument and software (PE Applied Biosystems). Reactions were done in triplicate, with GAPDH mRNA endogenous control in all experiments.
Statistics. Data are presented as means Ϯ SEM. One-way ANOVA, fully randomized design, was used to evaluate significant differences between groups, followed by post-hoc comparisons of group means by the HSD and LSD method (STATISTICA software, Ver. 6.0 StatSoft, Tulsa, OK). Statistical analysis was not performed for mRNA expression, because cDNA was prepared from pooled livers; SEM in these determinations shows variation in the assay.
Results

GC-1 Reduces HDL Cholesterol and Very Low-Density Lipoprotein
(VLDL) Triglyceride Levels in Euthyroid Mice. We first compared effects of GC-1 and T 3 administration on cholesterol and triglyceride metabolism in euthyroid chow-fed male mice. Both ligands yielded dose-dependent reductions of serum cholesterol (Fig. 1A) ; the response to GC-1 was stronger than T 3 at equimolar doses. Circulating cholesterol in rodents is largely contained in HDL. Chromatographic (SEC) analysis of pooled serum samples confirmed this and showed that GC-1 and T 3 reduce HDL cholesterol levels ( Fig. 1 B and C) . GC-1 had no effect on VLDL cholesterol, whereas T 3 increased VLDL cholesterol at the high doses, 24 or 97 nmol͞kg per day.
As seen in hypothyroid mice (16), GC-1 but not T 3 reduced serum triglyceride levels (Fig. 1D ). This was due to reductions in VLDL and LDL triglycerides (Fig. 1E) . Low doses of T 3 increased 
mmol͞liter). (E and F)
Serum lipoprotein patterns after separation by SEC. Individual serum was used (10 l), and triglyceride and glycerol content was determined. Data show mean Ϯ SEM. Note that GC-1 reduces VLDL triglycerides at all concentrations (E), whereas low concentrations of T 3 increase VLDL and higher concentrations reduce VLDL (F). A.U., arbitrary units.
VLDL triglycerides, although high concentrations of T 3 reversed this effect (Fig. 1F ) .
GC-1 Increases Hepatic HDL Receptor Levels and Stimulates Conver-
sion of Cholesterol to Bile Acids. The observation that GC-1 reduced serum HDL cholesterol prompted us to assay for hepatic expression of receptors that remove cholesterol from the circulation. LDLR activity, and transcripts were not affected by GC-1 or T 3 ( Fig. 6 and Table 3 , which are published as supporting information on the PNAS web site). However, both ligands increased levels of the HDL receptor SR-BI to ϩ240% of control with 48 nmol͞kg per day of GC-1 ( Fig. 2A) and ϩ150% with similar amounts of T 3 . Neither GC-1 nor T 3 affected SR-BI mRNA (Table 3) , suggesting this effect involves posttranscriptional mechanisms.
The large reduction of plasma HDL cholesterol induced by GC-1 and T 3 was not accompanied by increased intrahepatic cholesterol (Fig. 7A , which is published as supporting information on the PNAS web site), leading us to hypothesize that increased hepatic uptake of HDL-cholesterol via SR-BI is paralleled by elimination of cholesterol as bile acids. Conversion of cholesterol to bile acids is mediated by cholesterol 7␣-hydroxylase (CYP7A1), whose activity can be monitored by measuring serum levels of C4, an intermediate in bile acid synthesis (29) . In agreement with earlier data showing that TR␤ regulates CYP7A1 (5, 33, 34) , GC-1 increased serum C4 levels, reaching ϩ230% of control at 97 nmol͞kg per day GC-1 ( Fig.  2B) . T 3 treatment was less effective, reaching a maximal of 170% of control. These effects were paralleled by increases in hepatic CYP7A1 mRNA (Fig. 2C) .
GC-1 Regulates Expression of Genes Encoding Nuclear Transcription
Factors Involved in Hepatic Lipid Metabolism. We next examined GC-1 and T 3 effects on expression of genes encoding transcription factors involved in hepatic lipid metabolism. Bile acids induce expression of short heterodimerizing partner (SHP), which inhibits CYP7A1 expression by interaction with liver receptor homologue-1 (35) . GC-1 and T 3 reduced SHP mRNA levels 50 -60% (Fig. 2C) . Thus, TR␤ may stimulate bile acid synthesis by inhibiting SHP inhibition of CYP7A1 expression (36) .
SREBP-2 regulates intrahepatic cholesterol balance by stimulating transcription of the gene that encodes HMG CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, and LDLR, and its closely related homolog SREBP-1c regulates genes involved in triglyceride synthesis (37) . GC-1 and T 3 elicited a slight upregulation of SREBP-2 mRNA to 150% of control (Fig. 2D) . Nevertheless, expression of SREBP-2 target genes, HMG CoA reductase, and LDLR (38) was unaffected (Table 3) . Thus, T 3 and GC-1 modulate serum lipids independently of changes in SREBP-2 mRNA. In contrast, GC-1 and T 3 reduced levels of mRNA for SREBP-1c (Fig. 2D ) and of at least one gene regulated by SREBP1c, fatty acid synthetase (Table 3) . Thus, GC-1 and T 3 may inhibit hepatic fatty acid and triglyceride synthesis by repressing SREBP-1c gene expression.
GC-1 Reduces HDL Cholesterol and Triglyceride Levels in Hypercho-
lesterolemic Mice. We next investigated effects of T 3 and GC-1 in mice fed cholesterol or cholic acid that promotes hypercholesterolemia. We used 97 nmol͞kg per day of GC-1 and T 3 , which induced the strongest effects on serum C4 and SREBP-1c mRNA in nonsupplemented animals.
The cholesterol-and cholic acid-enriched diets resulted in the expected increase in serum cholesterol levels by 50% and 250%, respectively (Fig. 3A) , and GC-1 and T 3 blocked these increases. The cholesterol diet increased levels of VLDL and LDL, with no effect on HDL (Fig. 3B) . Here, GC-1 or T 3 reduced LDL and HDL cholesterol levels, with lesser effects on VLDL levels. The cholic acid diet increased VLDL and LDL cholesterol but reduced HDL cholesterol (Fig. 3C) ; GC-1 and T 3 reduced cholesterol levels in all fractions. Thus, GC-1 and T 3 reduce plasma HDL cholesterol levels in diet-induced hypercholesterolemia.
Cholesterol and cholic acid feeding resulted in respective 6-and 12-fold increases of hepatic cholesterol (Fig. 3D) . However, in line with their effects in chow-fed mice, neither TR ligand increased liver cholesterol levels and, in fact, slightly reduced liver cholesterol levels in cholic acid fed mice (Fig. 3D) .
The cholesterol and cholic acid diets reduced serum triglyceride levels ( Fig. 3E ) and increased hepatic triglyceride levels by 5-fold (Fig. 3F ) . The effect on serum triglyceride levels due to cholesterol feeding was partly reversed by T 3 but not GC-1, and that due to cholic acid feeding was not affected by either ligand (Fig. 3E) . T 3 doubled and GC-1 did not affect hepatic triglyceride levels. Thus, GC-1 does not further stimulate diet-induced triglyceride synthesis in liver.
GC-1 Increases Hepatic HDL Receptors and Stimulates
Bile Acid Synthesis in Hypercholesterolemic Mice. Next, we examined effects of T 3 and GC-1 on HDL receptor, bile acid conversion, and hepatic transcription factor expression in hypercholesterolemic mice. The cholesterol diet slightly reduced SR-BI protein levels (Fig. 4A) . Here, GC-1 treatment led to a doubling of SR-BI protein levels, whereas T 3 treatment led to only a minor increase. By contrast, the cholic acid diet increased SR-BI by 50%. Here, GC-1 increased SR-BI by a further 60%, whereas T 3 blunted the diet-induced increase. SR-BI mRNA levels increased by 40% with both diets but, paradoxically, GC-1 and T 3 reduced SR-BI mRNA compared with their respective control diets (Table 4 , which is published as supporting information on the PNAS web site). Thus, GC-1 enhances SR-BI protein levels via posttranscriptional effects in both chow-fed and hypercholesterolemic mice.
Both TR ligands increased serum C4 levels, indicating that they enhance bile acid synthesis in conditions of diet-induced hypercholesterolemia. The cholesterol diet slightly increased serum C4 levels and GC-1 or T 3 treatment induced a further 2-fold increase (Fig.  4B) . The cholic acid diet decreased C4 by 50%. GC-1 and T 3 treatments reversed this and further increased C4, leading to increases in serum C4 of 2-and 3-fold (Fig. 4B) .
Changes in serum C4 did not always correlate with levels of CYP7A1 mRNA (Fig. 4C) . The cholesterol diet only modestly increased serum C4 but induced CYP7A1 mRNA levels 3-fold, and GC-1 and T 3 treatment partially blunted this increase. The cholic acid diet suppressed CYP7A1 mRNA below that of controls. Here, GC-1 and T 3 reversed this suppression, leading to net induction of CYP7A1 mRNA.
T 3 and GC-1 influenced hepatic transcription factor expression in hypercholesterolemic mice. The cholesterol diet increased SHP mRNA by 50%. GC-1 and T 3 blunted this increase and reduced SHP mRNA below controls (Fig. 4C) . As expected, SHP mRNA levels were greatly increased by cholic acid feeding (Fig. 4C) . GC-1 and, to a larger extent, T 3 , reversed this induction, with SHP mRNA reduced to levels comparable to controls. Hepatic SREBP-1c mRNA increased by 150% and 200% in cholesterol-and cholic acid-fed mice (Fig. 4D) , likely a result of activation of liver X receptor (LXR) ␣ by cholesterol (39) . GC-1 and T 3 treatment reversed this increase in mice on both diets (Fig. 4D) . Neither ligand affected SREBP-2 mRNA (Fig. 4D) .
GC-1 Stimulates Fecal Excretion of Bile Acids.
To investigate whether TR␤ stimulation increased fecal excretion of bile acids and cholesterol, animals on the standard diet were treated with GC-1 or T 3 at 48 nmol͞kg per day, the dose that gave the strongest induction of SR-BI (Fig. 2A) . Feces were collected 24 h before and for the last 24 h of treatment. Compared with controls, animals treated with GC-1 exhibited a 45% increase and those with T 3 a 30% increase in fecal bile acid excretion (Fig. 5) . Neither ligand affected neutral sterol excretion (Fig 8, which is published as supporting information on the PNAS web site), suggesting that intestinal cholesterol absorption and hepatic biliary cholesterol secretion are not affected. Thus, only the bile acid synthetic pathway was affected. Accordingly, liver CYP7A1 mRNA levels correlated with bile acid excretion (Fig. 5) .
Discussion
In the present study, we show that the selective TR modulator GC-1 induces several important steps in RCT. We find that T 3 and GC-1 increase levels of hepatic SR-BI protein and, as previously reported for T 3 (40, 41) , CYP7A1 activity, and that this is associated with reduced circulating HDL cholesterol levels and increased fecal excretion of bile acids, with no change in fecal neutral sterol levels, a reflection of cholesterol excretion. Effects on SR-BI protein and CYP7A1 activity are observed in both normal and hypercholesterolemic mice. Thus, we propose that both ligands promote increased cholesterol influx into liver through the SR-B1 receptor, and that this cholesterol is channeled toward bile acid synthesis rather than directly to biliary cholesterol secretion.
Although GC-1 and T 3 induce several key steps in RCT, the extent to which they actually promote RCT is not clear, because we did not measure cholesterol synthesis. Thus, increased release of bile acids into the intestine could be secondary to increased cholesterol synthesis. Nevertheless, although TH administration does promote cholesterol synthesis in hypothyroid animals by increasing transcription and stability of HMG CoA reductase mRNA (see ref. 42 ), we did not detect similar effects, likely because we used euthyroid animals (Table 3) . Thus, unless T 3 or GC-1 exert unexpected posttranslational effects on HMG CoA reductase, it seems unlikely that the increased excretion of bile acids is secondary to enhanced synthesis of cholesterol. Expression of the Apo A1 gene, whose product encodes the major apolipoprotein in HDL, or the ABCA1 gene, whose product secretes cholesterol onto HDL (Table 3) , was also unaffected in our euthyroid mice model.
Our data are restricted to mice, so it is not clear whether similar effects occur in humans (43) . However, previous studies showed that elevated TH production and administration reduce plasma HDL in humans (44) (45) (46) (47) , even though TH can induce increases in mRNA for Apo A1 in euthyroid conditions (48) . Thus, it is possible that TH reduces HDL cholesterol by stimulating key steps in RCT also in humans.
TR effects upon RCT steps involve a mix of mechanisms. Increases in hepatic SR-BI protein levels result from posttranscriptional regulation; SR-BI mRNA levels were either unaffected or reduced by T 3 or GC-1. This is in line with previous studies showing that such mechanisms occur (49) (50) (51) . By contrast, T 3 and GC-1 effects on CYP7A1 activity were generally paralleled by increases in CYP7A1 mRNA, again in line with previous studies (33, 40) . The sole exception was after dietary cholesterol challenge, where T 3 -and GC-1 dependent increases in CYP7A1 activity were accompanied by decreases in CYP7A1 mRNA, emphasizing that multiple 5 . T3 and GC-1 increase bile acid excretion. Effects of GC-1 and T3 (48 nmol͞kg per day) on fecal bile acid excretion (because assays are from pools of samples from the animals, statistical variation cannot be reported) and hepatic CYP7A1 mRNA (mean Ϯ SEM from three separate cDNA synthesis from pooled RNA). We also measured fecal excretion of bile acids with a method based on ethanol extraction at boiling point followed by enzymaticcolorimetric assay and obtained similar results.
mechanisms of TR action are operative. Finally, we observe that T 3 and GC-1 reduce SHP mRNA levels, raising the possibility that both ligands induce CYP7A1 expression by blocking SHPdependent feedback inhibition of CYP7A1 transcription.
TH lowers plasma LDL in humans and rodents (47, 52, 53) , and both ligands we tested reduced cholesterol levels in all fractions in hypercholesterolemic mice. Nevertheless, although several studies show that TH induces LDLR in rodents (52, 54, 55), we did not detect changes in hepatic LDLR activity or mRNA. We speculate that our euthyroid model precludes this effect, and that other mechanisms that reduce plasma LDL may be active.
GC-1 displayed some useful properties that are distinct from T 3 . GC-1 elicited larger increases in SR-BI levels than T 3 . GC-1 also lowers serum and liver triglyceride levels more effectively than T 3 . The reasons for differences are not clear. Analysis of hepatic mRNA levels for proteins regulating triglyceride synthesis and secretion, DGAT-1, fatty acid synthase, SCD-1, MTP, and apoAV (Table 4 ) revealed no obvious differential actions. GC-1 fails to accumulate in adipose tissue (19) , so one possibility is that GC-1 fails to suppress lipoprotein lipase activity and reduce hydrolysis of serum triglycerides (56) or to promote enhanced ␤-adrenergic lipolysis, which increases delivery of nonesterified fatty acids to liver and promotes triglyceride synthesis (57) . GC-1 might influence serum and liver triglyceride levels via differential effects on the liver bile acid pool: bile acids reduce triglycerides via FXR-mediated induction of SHP and inhibition of SREBP-1c expression (58) . However, that both ligands reduce hepatic SHP mRNA levels in our experiments argues against this mechanism.
Our data also raise the possibility that TR␤-selective activators like GC-1 could be used in combination with other drugs. T 3 and GC-1 do not work like statins; neither alters hepatic cholesterol levels or enhances expression of the SREBP-2 target, and HMGCoA reductase. Thus, TR␤-selective activators in combination with statins might elicit larger reductions in serum cholesterol levels than obtained with either agent alone. The ability of GC-1 and T 3 to block diet-induced increases in hepatic SREBP-1c mRNA might also be useful. SREBP-1c expression is induced by LXR agonists, resulting in increases in serum triglyceride levels (59, 60) . However, LXR agonists elicit other actions that may be beneficial, such as inducing cholesterol removal from macrophages (61) . Thus, TR␤-selective agonists might act synergistically with LXR agonists on lipid metabolism and might also block the LXR agonist-induced increases in SREBP-1c expression and triglyceride levels.
The current observation that GC-1 stimulates key steps in RCT provides a previously undescribed feature to this ligand. Coupled with previous observations of lowered plasma cholesterol, triglycerides, and lipoprotein(a) and reduced obesity, this action might amplify potential antiatherogenic effects, which are observed in the absence of deleterious effects on heart, bone, and muscle. Our data suggest that GC-1 and similar ligands deserve further study as antiatherogenic agents.
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